Tender detail
Open-house medicine discount agreements for belimumab (ATC L04AG04)
Summary
AOK Bayern is offering non-exclusive, identical, non-negotiable medicine discount agreements covering the active substance belimumab (ATC L04AG04). The agreements may start from 1 January 2027 and end on 31 December 2028; they may be concluded during that period, no later than 3 November 2028. They may be terminated with one month’s notice to the end of a month, and may automatically cease to apply for the relevant period if a nationwide or state-level discount agreement for the same active substance takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.